391
Views
0
CrossRef citations to date
0
Altmetric
Commentary

All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential ‘perfect storm’

Pages 745-746 | Published online: 28 Apr 2010

The outcome of patients with therapy-related acute myeloid leukemia (t-AML) is generally poor, and allogeneic hematopoietic cell transplant may provide the only curative treatment [Citation1]. In striking contrast, the outcome for patients with therapy-related acute promyelocytic leukemia (t-APL) appears to be as favorable as that of patients with de novo APL when treated with all-trans retinoic acid (ATRA) plus anthracycline-based chemotherapy [Citation2,Citation3].

Information describing therapeutic approaches for patients with t-APL is important, since the incidence may be increasing, and efforts to minimize cytotoxic chemotherapy are a major focus of current clinical research in the field [Citation2,Citation4]. This particular subtype of AML generally occurs less than 3 years after treatment of the primary malignancy, and may occur after exposure to chemotherapy (usually the epipodophyllotoxins, anthracyclines, or anthracenediones), radiation therapy, or both. These agents induce cleavage of DNA by topoisomerase II at the translocation breakpoints in APL [Citation5–7]. In one recent small series, dyserythropoiesis or dysmegakaryopoiesis was identified in 11 of 12 patients [Citation8]. Two-thirds of the patients had a cytogenetic abnormality in addition to the characteristic t(15;17) (q22;q21). Interestingly, mutations of the FLT3 (FMS-like tyrosine kinase 3) gene, known to be relatively common in APL in general, were identified in 42% of cases. This observation provides the rationale for combining ATRA with a FLT3 inhibitor in such patients [Citation9].

Recent studies have suggested that treatment of patients with de novo APL with ATRA plus arsenic trioxide (ATO) is a very effective therapeutic strategy [Citation10]. Furthermore, conventional cytotoxic chemotherapy can be minimized and even potentially eliminated. It stands to reason that such treatment of patients with t-APL would be equally effective as that of patients with de novo APL. However, few data are available which address this issue.

Malhotra and colleagues from India report excellent outcomes of three patients with t-APL treated with the combination of ATRA and ATO [Citation11]. While the first patient's history is complicated, all three patients received three cycles of consolidation once in complete remission with ATRA and ATO, and all three patients received maintenance therapy, two with ATRA, 6-mercaptopurine, and methotrexate, and one with these agents plus ATO. Two of the three patients described in the letter by Malhotra and colleagues presented with high-risk disease (white blood cell count ≥10 000/μL), a subset of patients with a generally less favorable outcome when treated with standard ATRA plus anthracyclines.

The follow-up is short for all three patients, but the results are impressive enough to take notice. The optimal number of cycles of ATRA plus ATO to cure as many patients as possible is not known. Furthermore, it is not known if maintenance therapy is definitely required after induction and consolidation with ATRA plus ATO. Nevertheless, such an approach is particularly attractive in this setting. Patients with t-APL constitute a population for whom the avoidance of additional anthracycline-based chemotherapy is particularly important, since anthracyclines may have contributed to the development of the disease, potentially creating a ‘perfect storm.’ In addition, some patients may have reached their cumulative maximal dose of anthracyclines. The information reported by Dr. Malhotra and colleagues contributes to mounting evidence that ATRA plus ATO is emerging as a useful therapy for many patients with APL, and that the efficacy of this combination is not limited to patients with de novo disease. Further studies will need to be carried out to confirm these results in a larger population of patients. However, to avoid exposure to anthracyclines, so important in the current standard treatment of most patients with APL, or because some patients have reached their maximal cumulative dose, treatment of patients with t-APL with ATRA plus ATO is an appealing strategy to rescue patients from the potentially rough waters in the midst of a ‘perfect storm’ generated by exposure to additional toxic chemotherapy.

References

  • Yakub-Agha I, de La Salamoniere P, Ribaud P, et al Allogeneic bone transplantation for therapy-related myelodysplastic syndrome and acute myelogenous leukemia: a report of 70 patients—report of the French Society of bone marrow transplantation. J Clin Oncol 2000;18:963–971.
  • Beaumont M, Sanz M, Carli PM, et al Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123–2137.
  • Pulsoni A, Pagano L, Lo Coco F, et al Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972–1976.
  • Tsimberidou A-M, Kantargian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma 2006;47:2282–2288.
  • Mistry AR, Felix CA, Whitmarsh RJ, et al DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529–1538.
  • Hasan SK, Mays AN, , Ottone T, et al Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008;112:3383–3890.
  • Mays AN, Osheroff N, Xaio Y, et al Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2010;115:326–330.
  • Yin CC, Glassman AB, Lin P, et al Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol 2005;123:840–848.
  • Sohal J, Phan VT, Chan PV, et al A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 2003;101:3188–3197.
  • Ravandi F, Estey E, Jones D, et al Effective treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide, and gentuzumab ozogamicin. J Clin Oncol 2009;27:504–510.
  • Malhotra P, Varma N, Arora N, et al Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients. Leuk Lymphoma 2010;51:938–941.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.